Like most websites, we use cookies and other similar technologies for a number of reasons, such as keeping our website reliable and secure, personalizing content, providing social media features and to better understand how our site is used. By using our site, you are agreeing to our use of these tools. Please review our Privacy Policy to learn more. 

Skip to Content

For everyone's safety, masks are required for everyone in our facilities. This includes visitors and patients. View visitor policy.

Bryan Heart

To refer a patient to a Bryan Heart cardiologist or surgeon, call 402-483-3333.

Learn about Bryan Heart

the beat

The Beat:
A Bryan Heart Blog

The Beat is a monthly blog from Bryan Heart cardiologists to keep you informed on trending topics, advancements and news in heart care.

Subscribe to receive The Beat to your inbox monthly.

Pacemaker Advancements

Written by W. Michael Kutayli, MD, Bryan Heart Electrophysiologist

Leadless pacemakers represent the latest in device technology and have revolutionized the treatment of bradycardia in recent years. Bryan Heart has been at the forefront of this revolution from the beginning and remains at its leading edge.

Leadless Pacemaker Origins

Initially envisioned in the 1970s, leadless pacemakers were successfully implanted in dogs using a mercury battery powered capsule. With advanced battery technology, communication capability, and catheter-based delivery systems leadless pacemakers became a reality.

The Micra Transcatheter Pacing system (Medtronic) received FDA approval in April 2016. Bryan Heart electrophysiologist Andrew Merliss, MD, implanted the first leadless pacemaker in Nebraska on July 6, 2016.

Leadless pacemakers are:

  • 90% smaller than a transvenous pacemaker
  • A self- contained generator and electrode system
  • Implanted directly into the right ventricle via a femoral vein transcatheter approach
    • requires no chest incision or subcutaneous generator pocket

The Micra attaches to the right ventricle myocardium via four linear self-expanding nitinol tines. Low-molecular weight heparin is administered preoperatively and during the procedure to prevent thrombosis. Complications may occur related to femoral vein access or need for device repositioning; there is moderate risk of cardiac perforation with subsequent pericardial effusion. Patients and providers should be aware that although cardiac perforation is a rare complication following pacemaker system implant procedures, the risk of major complications following cardiac perforation may be higher in patients who receive leadless pacing systems vs. traditional transvenous pacemakers.

Benefits of Leadless Pacemakers

The primary advantage of a leadless pacemaker is the elimination of several complications associated with transvenous pacemakers and leads, such as:

  • Pocket infections
  • Hematoma
  • Lead dislodgement
  • Lead fracture

The leadless pacemaker also has cosmetic appeal because there is no chest incision or visible pacemaker pocket. Leadless pacemakers are also designed to be compatible with magnetic resonance imaging.

At present, leadless pacemakers provide only single-chamber ventricular pacing and lack defibrillation capacity. Leadless pacemakers may be suitable for patients with:

  • Permanent atrial fibrillation with bradycardia
  • Tachycardia-bradycardia syndrome or
  • Those who rarely require pacing

Until recently, leadless pacemakers were felt to be inappropriate for patients with certain forms of heart block.

Latest Leadless Pacers Hit the Market

Approved by the FDA in 2020, Micra AV™ looks like the original Micra. However, Micra AV™ has several additional and novel internal atrial sensing algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, providing “AV synchronous” pacing therapy. In a sense, it detects pressure changes that occur with atrial contraction—it has the ability to “listen” for intrinsic atrial activity.  The Micra AV™ also delivers an estimated average battery longevity of eight to 13 years, dependent on patient’s degree of AV block. The first Micra AV™ was implanted at Bryan on March 20, 2020.

Bryan Heart Continues to help Pioneer Advances in Leadless Pacing

Abbott recently announced new, late-breaking data from the global Leadless II IDE study evaluating Abbott's investigational Aveir leadless pacemaker in patients with certain abnormal heart rhythms. The data shows the Aveir device met its pre-specified primary endpoints and suggest that the Aveir system, once approved, could offer new benefits for patients who require the use of a pacemaker to treat slow heart rhythms.

Abbott's Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed. Abbott's investigational Aveir leadless pacemaker is currently being evaluated for FDA approval. Bryan Heart electrophysiologists will be involved in upcoming trials with the Aveir system that may eventually lead to the development of a leadless dual chamber pacemaker.

As always, Bryan Heart remains committed to providing the Midwest with the latest pacing technologies available.

We’re Here for You

For questions or to refer a patient, please call 402-483-3333.

michael kutayli md

W. Michael Kutayli, MD

W. Michael Kutayli, MD, is a cardiac electrophysiologist at Bryan Heart. Kutayli is a graduate of The University of South Dakota School of Medicine and joined Bryan Heart in 2010 after completing his residency at Creighton University School of Medicine and fellowships at Case Western Reserve University and Creighton University School of Medicine. He is certified with the American Board of Internal Medicine.

View Dr. Kutayli's physician profile.


Copyright 2022 Bryan Health. All rights reserved.